The FDA approval of Optune Pax represents a significant commercial opportunity, but investors should monitor whether the company can improve margins and achieve profitability as it invests heavily in clinical trials (KEYNOTE D58, LUNAR-2) and commercialization. The reinstatement of CMS billing privileges removes a near-term regulatory risk.
NVCR drugs
NVCR drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 26 $13.75entry
- T+1 · 9mo ago −0.58%α −0.13% · $13.67
- T+5 · 9mo ago +3.49%α +4.62% · $14.23
- T+20 · 8mo ago −14.47%α −8.07% · $11.76
- T+60 · 6mo ago +30.18%α +22.43% · $17.90
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
NovoCure reported 8% year-over-year revenue growth for Q4 and full year 2025, driven by increased active patients on therapy. The company received FDA approval for Optune Pax in locally advanced pancreatic cancer, a key milestone. Despite revenue growth, the company reported a net loss of $24.5 million in Q4 and guided for Adjusted EBITDA between -$20 million and $0 million in 2026 as it continues investing in clinical trials and commercialization.
Key Financial Metrics
Key Facts
- Full year 2025 revenue was $655.4 million, up 8% YoY; Q4 revenue was $174.4 million, also up 8% YoY
- FDA approved Optune Pax for locally advanced pancreatic cancer in February 2026
- Q4 2025 net loss was $24.5 million with loss per share of $0.22
- Gross margin declined to 76% from 79% in prior year due to HFE array rollout, pre-reimbursement NSCLC costs, and tariffs
- 2026 guidance: revenue of $675M-$705M and Adjusted EBITDA of -$20M to $0M
- CMS billing privileges were briefly revoked then reinstated retroactively; company expects no revenue impact
Financial Impact
Revenue growth of 8% YoY to $655.4 million in 2025, but continued losses with Q4 net loss of $24.5 million and gross margin compression from 79% to 76%
Segment Breakdown
| Segment | Revenue |
|---|---|
| Optune Gio | $174.4M |
| Optune Lua | $3.5M |
Risk Factors
- Continued gross margin pressure from HFE array rollout and pre-reimbursement costs
- Heavy R&D spending ($60.9M in Q4, up 19% YoY) delaying path to profitability
- Dependence on successful clinical trial outcomes and reimbursement approvals for new indications
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001645113-26-000018 |
| Document: nvcr-20260226.htm | 0001645113-26-000018 |
| Document: 0001645113-26-000018-index-headers.html | 0001645113-26-000018 |
| Document: 0001645113-26-000018-index.html | 0001645113-26-000018 |
| Document: 0001645113-26-000018.txt | 0001645113-26-000018 |
Track record
20 reports on NVCR
5 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +19.75% at T+20 after the Feb 27, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $11.83 to $11.30 Now $11.30 −4.48% ▼ −4.48% −2.57% vs SPY
- Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $12.53 to $11.81 Now $11.30 +9.82% ▲ +5.75% +5.38% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $13.11 to $13.15 Now $11.30 −13.81% ▲ +0.31% +2.08% vs SPY
- Oct 1, 20266w ago 8-K Bullish 6/10 Entry $15.92 to $14.94 Now $11.30 −29.02% ▼ −6.16% −6.90% vs SPY
- Sep 9, 20269w ago 8-K Neutral 2/10 Entry $15.63 to $15.35 Now $11.30 −27.70% ▼ −1.79% −1.19% vs SPY
- Sep 1, 202610w ago 8-K Neutral 3/10 Entry $17.38 to $17.83 Now $11.30 −34.98% ▲ +2.59% +2.15% vs SPY
- Jul 23, 202616w ago 8-K Bullish 7/10 Entry $19.99 to $17.65 Now $11.30 −43.47% ▼ −11.71% −11.81% vs SPY
- Jun 30, 202619w ago 8-K Bullish 7/10 Entry $15.15 to $15.78 Now $11.30 −25.41% ▲ +4.16% +4.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers